Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 16/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | TDO2 | P48775 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2190717 | 0.85 | IDO1 (0.62) | IDO1TDO2 | |
| SCHEMBL2191269 | 0.79 | IDO1 (0.57) | IDO1TDO2 | |
| SCHEMBL2191191 | 0.77 | KMT2A (0.58) | IDO1TDO2 | |
| SCHEMBL2192875 | 0.77 | IDO1 (0.52) | IDO1TDO2 | |
| SCHEMBL2192634 | 0.77 | IDO1 (0.55) | IDO1TDO2 | |
| SCHEMBL2190877 | 0.77 | SMN1; SMN2 (0.75) | SMN1; SMN2 | |
| SCHEMBL2190879 | 0.77 | SMN1; SMN2 (0.75) | SMN1; SMN2 | |
| SCHEMBL2183732 | 0.77 | IDO1 (0.57) | IDO1TDO2 | |
| SCHEMBL2184143 | 0.76 | IDO1 (0.59) | IDO1TDO2 | |
| SCHEMBL2185680 | 0.76 | IDO1 (0.59) | IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064207-B1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORP (US) | 2013-11-06 | — | — | EP | claimed |
| US-8377976-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2013-02-19 | — | — | US | claimed |
| US-20110172279-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-07-14 | — | — | US | claimed |
| EP-2064207-A2 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation (US) | 2009-06-03 | — | — | EP | claimed |
| US-20080125470-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-05-29 | — | — | US | claimed |
| WO-2008036642-A2 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-03-27 | — | — | WO | claimed |
| EP-2064207-B1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORP (US) | 2013-11-06 | — | — | EP | disclosed |
| US-8377976-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110172279-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-07-14 | — | — | US | disclosed |
| US-20080125470-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172279-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, HNMT | IDO1 1/4885SMN1; SMN2 3241/4885TDO2 15/4885 |
| US-20080125470-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, HNMT | IDO1 1/4885SMN1; SMN2 3241/4885TDO2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.